Cyclosporine and tacrolimus in dermatology

Dermatologic Clinics

Volumn 19, Issue 1, 2001, Pages 119-137

  Clay Cather, Jennifer ^a   Abramovits, William ^a   Menter, Alan ^a,b  

^a Texas Dermatology Associates PA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ALOPECIA; ALOPECIA AREATA; ATOPIC DERMATITIS; BEHCET DISEASE; BULLOUS SKIN DISEASE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG METABOLISM; DRUG STRUCTURE; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; PEMPHIGOID; PEMPHIGUS; PHOTODERMATOSIS; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; TOXIC EPIDERMAL NECROLYSIS;

EID: 0035171504     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70234-5     Document Type: Article

References (167)

1. Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum
2. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK506)
3. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children
4. Bekersky I: A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients
5. Cyclosporine in the treatment of an unusual case of juvenile systemic sclerosis
6. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
7. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK 506 ointment
8. Risk of cancer with cyclosporine in psoriasis
9. Effective treatment of persistent papular acantholytic dermatosis with cyclosporine
10. Cyclosporin A in metastatic Crohn's disease
11. Combination therapy for psoriasis
12. Cyclosporin: New immunosuppressive agent in bullous pemphigoid and pemphigus
13. Scleromyxedema
14. Cutaneous lesions in 67 cyclosporine-treated renal transplant recipients
15. Cyclosporine nephrotoxicity: Implications for dermatology
16. Clinical aspects: Preliminary experience with a novel oral formulation of cyclosporin (Neoral)
17. Cyclosporine in severe childhood atopic dermatitis: A multicenter study
18. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
19. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): A multicentre study
20. Nodular prurigo responds to cyclosporin
21. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996
22. Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis
23. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children
24. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis
25. Cyclosporin-responsive hidradenitis suppurativa
26. Life-threatening psoriasis relapse on withdrawal of cyclosporin
27. Treatment of thrombophlebitis of Behcet's disease with low dose cyclosporin A
28. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: Rationale and preliminary results
29. Cutaneous Allergy. Cambridge
30. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune
31. Reactions and interactions of some commonly used systemic drugs in dermatology
32. Cyclosporin A in progressive systemic sclerosis
33. Bullous pemphigoid and response to cyclosporine
34. Pemphigus foliaceous and response to cyclosporin
35. Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis
36. Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-pustular pustulosis
37. Comparative pathophysiology and histopathology of cyclosporine nephrotoxicity
38. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine
39. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in a patient with Behcet's disease treated with cyclosporin
40. Human hand allograft: Report on first 6 months
41. Immunosuppressive agents in dermatology: An update
42. Cyclosporin A therapy for severe solar urticaria
43. Topical cyclosporine for oral mucosal disorders
44. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis
45. Treatment of pyoderma gangremosum with cyclosporine: Results in seven patients
46. Safety issues with cyclosporine
47. Duration of remission during maintenance cyclosporine therapy for psoriasis: Relationship to maintenance dose and degree of improvement during initial therapy
48. Cyclosporine improves psoriasis in a double-blind study
49. Acne: A potential side effect of cyclosporine A therapy
50. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis
51. Systemic tacrilomus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
52. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases
53. Cyclosporin for the treatment of granuloma annulare
54. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method
55. Management of patients and side effects during cyclosporine therapy for cutaneous disorders
56. Prolonged survival of rat skin allograft by treatment with FK506 ointment
57. Cyclosporine therapy for psoriasis: Serum creatinine, measurements are an unreliable predictor of decreased renal function
58. Use of topical cyclosporin in oral pemphigus
59. Coexisting lichen planus and subacute cutaneous lupus erythematosus
60. Long-term follow up of eczema patients treated with cyclosporine
61. Successful long-term use of cyclosporin A in HIV-induced pityriasis lichenoides chronica
62. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses
63. Generalized pustular psoriasis in relation to withdrawal of cyclosporin A
64. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin
65. Toxic epidermal necrolysis treated with cyclosporin
66. Cyclosporine in the treatment of generalized granuloma annulare
67. Safety and efficacy of short course therapy with cyclosporin A microemulsion formulation in chronic plaque psoriasis: An interim analysis
68. Treatment of severe lichen planus with cyclosporine
69. Cyclosporine in nonpsoriatic dermatoses
70. Treatment of glucocorticoid-dependent Takayasu's arteritis with cyclosporin
71. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy
72. Verruca vullgaris developing during cyclosporin therapy for psoriasis vulgaris
73. Short-term cyclosporine for chronic idiopathic urticaria
74. Cytophagic histiocytic panniculitis improved by combined CHOP and cyclosporine treatment
75. Successful treatment of a patient with febrile, lobular panniculitis (Weber-Christian disease) with oral cyclosporine A: Implications for pathogenesis and therapy
76. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor
77. Cyclosporin-induced trichomegaly of accessory lashes as a cause of ocular irritation
78. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis
79. Acne conglobata: Treatment with isotretinoin, colchicine, and cyclosporin as compared with surgical intervention
80. Successful therapy of refractory graft versus host disease with tacrolimus and psoralen plus ultraviolet light
81. Successful treatment of Kimura's disease with cyclosporine
82. Potential drug interactions with cyclosporine
83. Cyclosporine in dermatology: Pharmacology and clinical use
84. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis
85. Tacrolimus: A new immunosuppressive agent
86. Successful treatment of severe recurrent Reiter's syndrome with cyclosporine
87. Pulmonary infiltrates recovered by FK506 in a patient with Behcet's disease
88. Neoral in psoriasis therapy: Toward a new perspective
89. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
90. Cyclosporine: What clinicians need to know
91. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis
92. Efficacy and safety of oral cyclosporin A (CyA:Sandimmun) for long-term treatment of chronic severe plaque psoriasis
93. Use of newer immunosuppressive agents in dermatology
94. Topical FK506 - Clinical potential or laboratory curiosity?
95. Inhibition of contact allergy reactions by topical FK506
96. Topical tacrolimus (FK506): Percutaneous absorption and effect on allergic and irritant contact dermatitis
97. Absorption of topical tacrilomus (FK506) in vitro through human skin: Comparison with cyclosporin A
98. Tacrolimus (FK506): Experience in dermatology
99. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
100. Severe lichen planus clears with very low-dose cyclosporin
101. Cyclosporine in the treatment of dermatologic disease: An update
102. Subcutaneous sarcoidosis worsened by cyclosporin treatment for pyoderma gangrenosum
103. Initiating Neoral therapy
104. Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure
105. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
106. Generalized pustular psoriasis following a short course of cyclosporin
107. Cyclosporine in scleroderma
108. Topical FK506: A potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model
109. In vivo depletion of CD8 + T cells restores hair growth in the DEBR model for alopecia areata
110. Rational, sequential and combination regimens in the treatment of psoriasis
111. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine
112. Cyclosporin A for psoriasis
113. Cyclosporin A for psoriasis
114. Treatment of hypereosinophilic syndrome in a child using cyclosporine: Implication for a primary T-cell abnormality
115. Tacrolimus ointment for atopic dermatitis
116. Metabolic effects of FK506 in patients with severe psoriasis. Short term follow-up of seven patients
117. Actinic reticuloid: Response to cyclosporine
118. Purpura pigmentosa chronica successfully treated with oral cyclosporin A
119. Side effects of systemic cyclosporine in patients not undergoing transplantation
120. Cancers and cyclosporin A: Anecdotal evidence and ethical concerns
121. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?
122. Acrodermatitis continua type of pustular psoriasis responds to low-dose cyclosporine
123. Low dose cyclosporine A in the treatment of disabling morphea
124. Tacrolimus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation
125. Renall function after 10 years treatment with cyclosporin for psoriasis
126. Topical tacrolimus for pyoderma gangrenosum
127. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis
128. Tacrilomus ointment improves psoriasis in a microplaque assay
129. Drug-induced TEN treated with CyA
130. Topical cyclosporin A fails to improve alopecia areata: A double blind study
131. Cyclosporine for severe psoriasis: Efficacy and prospective renal function
132. Cyclosporin in less common immune-mediated skin diseases
133. Tacrolimus: The drug for the turn of the millennium?
134. A short-term trial of tacrolimus ointment for atopic dermatitis
135. Cyclosporine - Relationship of side effects to mode of action
136. Differential effects of FK506 and cyclosporine on hair regrowth in the DEBR model for alopecia areata
137. A phase II trial of FK506 (tacrolimus) on refractory uveitis associated with Behcet's disease and allied conditions
138. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease
139. Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus
140. Comparison of two cyclosporin formulations in healthy volunteers: Bioequivalence of new Sang-35 formulation and Neoral
141. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: A clinical and immunopathologic evaluation
142. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis
143. Effect of obesity on cyclosporine trough concentrations in psoriasis patients
144. Maintenance therapy with Neoral
145. Cyclosporine as maintenance therapy in patients with severe psoriasis
146. Can maintenance cyclosporine be used in psoriasis without decreasing renal function?
147. Ulcerating necrobiosis lipoidica resolving in response to cyclosporin-A
148. Nephrotic syndrome associated with hypocomplementaemic urticarial vasculitis syndrome: Successful treatment with cyclosporin A
149. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: An open-label extension study
150. Cyclosporine therapy in Behcet's disease
151. Antipruritic effect of oral cyclosporin A in essential senile pruritus
152. Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms
153. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria
154. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
155. Erosive mucosal lichen planus: Response to topical treatment with tacrolimus
156. Psoriasis therapy after remission: The next step
157. Cyclosporine therapy of life-threatening cicatricial pemphigoid affecting the respiratory tract
158. Peripheral ulcerative keratitis - An extracutaneous neutrophilic disorder: Report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy
159. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent
160. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants
161. Multiple benign keratoses during cyclosporin therapy for psoriasis
162. Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin
163. Topical immunosuppression in skin grafting with FK506 ointment
164. Cyclosporine-associated lymphoma
165. Toxic epidermal necrolysis associated with severe hypocalcemia, and treated with cyclosporin
166. Topical tacroimus is not effective in chronic plaque psoriasis: A pilot study